HLA
RPTX

Hamilton Lane Advisors’s Repare Therapeutics RPTX Stock Holding History

Hamilton Lane Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,986
Closed -$337K – 88
2021
Q1 		$337K Buy
+10,986
New +$373K 0.11% 61

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Hamilton Lane Advisors's RPTX Position: Q2 2021 in Review

Hamilton Lane Advisors sold out of Repare Therapeutics (RPTX) in Q2 2021, closing a stake of 10,986 shares — an estimated $337K sold.

Hamilton Lane Advisors first reported a position in RPTX in Q1 2021 and held it in 1 quarter. The position peaked at $337K in Q1 2021. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2021.

  • Hamilton Lane Advisors reported no remaining Repare Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 10,986 Repare Therapeutics shares in Q2 2021, an estimated $337K.
  • Hamilton Lane Advisors first reported a position in Repare Therapeutics in Q1 2021 and held it in 1 quarter.
  • Hamilton Lane Advisors's Repare Therapeutics position peaked at $337K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2021.

Based on Hamilton Lane Advisors's 13F filing for Q2 2021, filed 20 Jul 2021.